Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Genmab told attendees at the Jefferies London Healthcare Conference that it is concentrating on late‑stage assets—EPKINLY, Rina‑S, Acasunlimab and petosemtamab (Peto), the latter intended to be added via the planned acquisition of Merus—while commercializing Tivdak across key European markets. Management said the Tivdak rollout is intended to create a commercial foothold ahead of a Rina‑S launch targeted in about 1.5 years, and positioned Peto as a near‑term pipeline addition through the Merus deal. The update frames Genmab as transitioning to a pipeline‑driven company with imminent regulatory and commercial catalysts that could materially affect near‑term revenue trajectories.

Analysis

At the Jefferies London Healthcare Conference Genmab management (CEO Jan van de Winkel, CFO Anthony Pagano) said the company is concentrating on late‑stage programs EPKINLY, Rina‑S, Acasunlimab and petosemtamab (Peto), the latter intended to be added via the planned acquisition of Merus, while commercially rolling out Tivdak across key European markets. Management explicitly framed the Tivdak rollout as a means to create a commercial foothold ahead of a Rina‑S launch targeted in approximately 1.5 years, signaling a coordinated regulatory and commercial timeline. The update positions Genmab as increasingly pipeline‑driven with a sequence of near‑term catalysts tied to the Merus transaction, late‑stage clinical/regulatory readouts and European commercial execution. Sentiment and market‑impact signals provided with the release are moderately positive (sentiment score 0.4, market_impact_score 0.33), implying investor optimism but a likely muted immediate share reaction absent definitive milestones; key risks are transaction execution, integration of Peto and the ability of Tivdak to establish repeatable European uptake.

Key Decisions for Investors

• Monitor the Merus acquisition progress and any regulatory milestones for petosemtamab closely, as the deal and approvals are a primary driver of near‑term pipeline value
• Track Tivdak early commercial metrics in the named European markets as a read on Genmab's ability to build a commercial infrastructure ahead of the Rina‑S launch in ~1.5 years
• Consider selective accumulation ahead of major de‑risking events (approval decisions, pivotal readouts or clear commercial uptake) but size positions conservatively given execution and integration risks
• Use event‑based hedges or wait for concrete evidence of Tivdak commercial traction or Merus deal completion if you prefer lower volatility exposure, since market impact is modest at this stage